search button
Open Access

A role for serum cytokines and cell adhesion molecules in the non‑invasive diagnosis of colorectal cancer

  • Authors:
    • Ovidiu Farc
    • Ioana Berindan-Neagoe
    • Florin Zaharie
    • Liviuta Budisan
    • Oana Zanoaga
    • Victor Cristea

  • View Affiliations

  • Published online on: July 26, 2022     https://doi.org/10.3892/ol.2022.13443
  • Article Number: 323

  • Copyright: © Farc et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Colorectal cancer (CRC) remains a major cause of cancer‑related mortality. Consequently, new diagnostic and therapeutic approaches are being investigated including the serum levels of cytokines and other molecules, although the results are often inconclusive. Thus, the present study aimed to determine whether serum level of cytokines, cell adhesion molecules or matrix metalloproteinases (MMPs), alone or in combination, may contribute to the non‑invasive diagnosis of CRC. The serum levels of nine cytokines [ILs; IL‑1β, IL‑4, IL‑6, IL‑8, IL‑10, IL‑17, IL‑22 and IL‑33, and interferon (IFN)‑γ], two cell adhesion molecules (intercellular adhesion molecule‑1 and P‑selectin) and an MMP‑7 were measured by ELISA in 33 patients with CRC and 35 healthy controls. Combined capacity of all molecules to detect the presence of CRC was assessed by logistic regression. Molecules and molecule combinations were tested for all stages and tumor grades. A significant increase was identified for IL‑8 in patients compared with healthy controls; IL‑10 was found to be significantly decreased. The biomarker potential of each significantly modified molecule was tested: IL‑8 had a sensitivity of 0.865, a specificity of 0.600 and an area under the curve (AUC) of 0.777; for IL‑10, sensitivity was 0.65, specificity was 0.69, with an AUC of 0.689. Logistic regression determined the best discriminative potential between patients and control groups for the combination IL‑4 + IL‑6 + IL‑8 + IFN‑γ, with 0.97 sensitivity and 0.58 specificity. For the early stages of CRC, the combination IL‑6 + IL‑8 + IL‑22 showed good performance. It was concluded that increased IL‑8 had potential as single biomarker in CRC. Cytokine combinations are superior to single cytokine analysis in showing the presence of CRC.
View Figures
View References

Related Articles

Journal Cover

September-2022
Volume 24 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Farc O, Berindan-Neagoe I, Zaharie F, Budisan L, Zanoaga O and Cristea V: A role for serum cytokines and cell adhesion molecules in the non‑invasive diagnosis of colorectal cancer. Oncol Lett 24: 323, 2022
APA
Farc, O., Berindan-Neagoe, I., Zaharie, F., Budisan, L., Zanoaga, O., & Cristea, V. (2022). A role for serum cytokines and cell adhesion molecules in the non‑invasive diagnosis of colorectal cancer. Oncology Letters, 24, 323. https://doi.org/10.3892/ol.2022.13443
MLA
Farc, O., Berindan-Neagoe, I., Zaharie, F., Budisan, L., Zanoaga, O., Cristea, V."A role for serum cytokines and cell adhesion molecules in the non‑invasive diagnosis of colorectal cancer". Oncology Letters 24.3 (2022): 323.
Chicago
Farc, O., Berindan-Neagoe, I., Zaharie, F., Budisan, L., Zanoaga, O., Cristea, V."A role for serum cytokines and cell adhesion molecules in the non‑invasive diagnosis of colorectal cancer". Oncology Letters 24, no. 3 (2022): 323. https://doi.org/10.3892/ol.2022.13443